• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体抑制剂对阿瑟斯反应部位补体介导的血管损伤的抑制作用。

Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors.

作者信息

Asghar S S, Dingemans K P, Kammeijer A, Faber W R, Abdel Mawla M Y

出版信息

Complement. 1986;3(1):40-8. doi: 10.1159/000467876.

DOI:10.1159/000467876
PMID:2943553
Abstract

Certain complement inhibitors, namely chlorpromazine, suramin, 2-hydroxystilbamidine and chlorophenothiazine sulphonate were tested for their ability to suppress complement deposition and vascular injury at the site of an Arthus reaction. Deposition of complement was suppressed in the order 2-hydroxystilbamidine greater than suramin greater than chlorpromazine. All the above mentioned four compounds strongly protected vascular injury as observed by electron microscopic studies. At Arthus reaction sites prepared without drug treatment venules ranged from normal to severely altered and damaged. Discontinuities in endothelial linings varied from small to longer stretches. In the latter situation remaining endothelial cells were degenerated and endothelial remnants did not have an intact basal lamina. After treatment with the above complement inhibitors, at arthus reaction sites some venules appeared normal, whereas others were altered but in all cases the endothelium and its basal lamina remained intact.

摘要

对某些补体抑制剂,即氯丙嗪、苏拉明、2-羟基二脒基苯和氯吩噻嗪磺酸盐,进行了测试,以考察它们抑制Arthus反应部位补体沉积和血管损伤的能力。补体沉积的抑制程度依次为:2-羟基二脒基苯>苏拉明>氯丙嗪。电子显微镜研究表明,上述四种化合物均能强烈保护血管免受损伤。在未经药物处理的Arthus反应部位,小静脉从正常到严重改变和受损不等。内皮衬里的不连续性从小段到较长段不等。在后一种情况下,剩余的内皮细胞发生退化,内皮残余物没有完整的基底层。用上述补体抑制剂处理后,在Arthus反应部位,一些小静脉看起来正常,而另一些则有改变,但在所有情况下,内皮及其基底层均保持完整。

相似文献

1
Suppression of complement-mediated vascular injury at Arthus reaction sites by complement inhibitors.补体抑制剂对阿瑟斯反应部位补体介导的血管损伤的抑制作用。
Complement. 1986;3(1):40-8. doi: 10.1159/000467876.
2
Suppression of vascular injury at the Arthus reaction site by a complement inhibitor, 5,5',5''-(1,3,6-naphthalene-triyl-tris[sulfonylimino])-tris (1,3-benzene disulfonic acid) hexasodium salt.补体抑制剂5,5',5''-(1,3,6-萘三基-三[磺酰亚氨基])-三(1,3-苯二磺酸)六钠盐对阿瑟斯反应部位血管损伤的抑制作用
Complement Inflamm. 1991;8(1):50-9. doi: 10.1159/000463177.
3
P-selectin requirement for neutrophil accumulation and injury in the direct passive Arthus reaction.直接被动Arthus反应中中性粒细胞聚集和损伤对P-选择素的需求。
Clin Exp Immunol. 1998 May;112(2):281-6. doi: 10.1046/j.1365-2249.1998.00584.x.
4
Suppression of active Arthus reaction by colchicine.秋水仙碱对活性阿瑟斯反应的抑制作用。
Br J Dermatol. 1981 Sep;105(3):279-83. doi: 10.1111/j.1365-2133.1981.tb01286.x.
5
Inhibition of cellular infiltration at the site of Arthus reaction by chlorpromazine. Use of a new area integration technique.
Int J Immunopharmacol. 1990;12(6):685-90. doi: 10.1016/0192-0561(90)90106-w.
6
STUDIES ON THE LOCALIZATION OF CIRCULATING ANTIGEN-ANTIBODY COMPLEXES AND OTHER MACROMOLECULES IN VESSELS. I. STRUCTURAL STUDIES.循环抗原 - 抗体复合物及其他大分子在血管中的定位研究。I. 结构研究。
J Exp Med. 1963 Oct 1;118(4):489-502. doi: 10.1084/jem.118.4.489.
7
The Arthus reaction in rodents: species-specific requirement of complement.
J Immunol. 2000 Jan 1;164(1):463-8. doi: 10.4049/jimmunol.164.1.463.
8
Disappearance of immunoglobulin and complement from the Arthus reaction and its relevance to studies of vasculitis in man.
Br J Dermatol. 1971 Feb;84(2):106-9. doi: 10.1111/j.1365-2133.1971.tb06851.x.
9
Targeting complement in therapy.治疗中针对补体系统
Immunol Rev. 2001 Apr;180:177-89. doi: 10.1034/j.1600-065x.2001.1800116.x.
10
Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.口服或局部给予小分子C5a受体拮抗剂后对大鼠免疫复合物介导的皮肤炎症的抑制作用
Br J Pharmacol. 2001 Dec;134(8):1778-86. doi: 10.1038/sj.bjp.0704417.